Review
doi: 10.1016/j.addr.2006.07.021. Epub 2006 Sep 15.Current status of gene delivery and gene therapy in lacrimal gland using viral vectors
Affiliations
- PMID:17056149
- PMCID: PMC1773022
- DOI: 10.1016/j.addr.2006.07.021
Item in Clipboard
Review
Current status of gene delivery and gene therapy in lacrimal gland using viral vectors
Shivaram Selvam et al. Adv Drug Deliv Rev..
Display options
Format
Display options
Format
Abstract
Gene delivery is one of the biggest challenges in the field of gene therapy. It involves the efficient transfer of transgenes into somatic cells for therapeutic purposes. A few major drawbacks in gene delivery include inefficient gene transfer and lack of sustained transgene expression. However, the classical method of using viral vectors for gene transfer has circumvented some of these issues. Several kinds of viruses, including retrovirus, adenovirus, adeno-associated virus, and herpes simplex virus, have been manipulated for use in gene transfer and gene therapy applications. The transfer of genetic material into lacrimal epithelial cells and tissues, both in vitro and in vivo, has been critical for the study of tear secretory mechanisms and autoimmunity of the lacrimal gland. These studies will help in the development of therapeutic interventions for autoimmune disorders such as Sjögren's syndrome and dry eye syndromes which are associated with lacrimal dysfunction. These studies are also critical for future endeavors which utilize the lacrimal gland as a reservoir for the production of therapeutic factors which can be released in tears, providing treatment for diseases of the cornea and posterior segment. This review will discuss the developments related to gene delivery and gene therapy in the lacrimal gland using several viral vector systems.
Figures
In vitro evaluation of anti-inflammatory gene therapy. This schematic describes an in vitro method for activating autologous lymphocytes in a mixed cell reaction and suppression of the lymphocyte activation by gene transfer. [Ref: 37].
This schematic describes the method used to induce autoimmune dacryoadenitis and the effect of gene therapy on the clinical symptoms and gland histopathology [Ref: 46,75,19].
Similar articles
- Viral vectors for gene delivery and gene therapy within the endocrine system.Stone D, David A, Bolognani F, Lowenstein PR, Castro MG.Stone D, et al.J Endocrinol. 2000 Feb;164(2):103-18. doi: 10.1677/joe.0.1640103.J Endocrinol. 2000.PMID:10657846Review.
- Advances in vector-mediated gene transfer.Baum BJ, Goldsmith CM, Kok MR, Lodde BM, van Mello NM, Voutetakis A, Wang J, Yamano S, Zheng C.Baum BJ, et al.Immunol Lett. 2003 Dec 15;90(2-3):145-9. doi: 10.1016/j.imlet.2003.08.006.Immunol Lett. 2003.PMID:14687716Review.
- Prophylactic effect of IL-10 gene transfer on induced autoimmune dacryoadenitis.Zhu Z, Stevenson D, Schechter JE, Mircheff AK, Ritter T, Labree L, Trousdale MD.Zhu Z, et al.Invest Ophthalmol Vis Sci. 2004 May;45(5):1375-81. doi: 10.1167/iovs.03-0755.Invest Ophthalmol Vis Sci. 2004.PMID:15111591
- Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjögren's syndrome.Kok MR, Yamano S, Lodde BM, Wang J, Couwenhoven RI, Yakar S, Voutetakis A, Leroith D, Schmidt M, Afione S, Pillemer SR, Tsutsui MT, Tak PP, Chiorini JA, Baum BJ.Kok MR, et al.Hum Gene Ther. 2003 Nov 20;14(17):1605-18. doi: 10.1089/104303403322542257.Hum Gene Ther. 2003.PMID:14633403
- [Transcatheter delivery of recombinant adenovirus vector containing exogenous aquaporin gene in treatment of Sjögren's syndrome].He H, Zhang J, Fan Y, Sun X, Zhu Y.He H, et al.Zhejiang Da Xue Xue Bao Yi Xue Ban. 2016 Jan;45(1):86-90, 97. doi: 10.3785/j.issn.1008-9292.2016.01.14.Zhejiang Da Xue Xue Bao Yi Xue Ban. 2016.PMID:27045247Free PMC article.Review.Chinese.
Cited by
- An efficient nonviral gene-delivery vector based on hyperbranched cationic glycogen derivatives.Liang X, Ren X, Liu Z, Liu Y, Wang J, Wang J, Zhang LM, Deng DY, Quan D, Yang L.Liang X, et al.Int J Nanomedicine. 2014 Jan 31;9:419-35. doi: 10.2147/IJN.S51919. eCollection 2014.Int J Nanomedicine. 2014.PMID:24520193Free PMC article.
- Gene Therapy in the Anterior Eye Segment.Amador C, Shah R, Ghiam S, Kramerov AA, Ljubimov AV.Amador C, et al.Curr Gene Ther. 2022;22(2):104-131. doi: 10.2174/1566523221666210423084233.Curr Gene Ther. 2022.PMID:33902406Free PMC article.Review.
- A targeted therapy for melanoma by graphene oxide composite with microRNA carrier.Liu C, Xie H, Yu J, Chen X, Tang S, Sun L, Chen X, Peng D, Zhang X, Zhou J.Liu C, et al.Drug Des Devel Ther. 2018 Sep 21;12:3095-3106. doi: 10.2147/DDDT.S160088. eCollection 2018.Drug Des Devel Ther. 2018.PMID:30275686Free PMC article.
- Novel insights into gene therapy in the cornea.Mohan RR, Martin LM, Sinha NR.Mohan RR, et al.Exp Eye Res. 2021 Jan;202:108361. doi: 10.1016/j.exer.2020.108361. Epub 2020 Nov 16.Exp Eye Res. 2021.PMID:33212142Free PMC article.Review.
- Synthesis and properties of a novel methoxy poly(ethylene glycol)-modified galactosylated chitosan derivative.Zhang T, Yu YY, Li D, Peng R, Li Y, Jiang Q, Dai P, Gao R.Zhang T, et al.J Mater Sci Mater Med. 2009 Mar;20(3):673-80. doi: 10.1007/s10856-008-3620-1. Epub 2008 Oct 24.J Mater Sci Mater Med. 2009.PMID:18949535
References
- Pawliuk R, Westerman KA, Fabry ME, Payen E, Tighe R, Bouhassira EE, Acharya SA, Ellis J, London IM, Eaves CJ, Humphries RK, Beuzard Y, Nagel RL, Leboulch P. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science. 2001;294:2368–2371. - PubMed
- Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bousso P, Deist FL, Fischer A. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288:669–672. - PubMed
- Bolstad AI, Jonsson R. Gene therapeutics in Sjogren's syndrome. Expert Opin Biol Ther. 2005;5:763–772. - PubMed
- Adriaansen J, Vervoordeldonk MJ, Tak PP. Gene therapy as a therapeutic approach for the treatment of rheumatoid arthritis: innovative vectors and therapeutic genes. Rheumatology. 2006 Mar 29; (Epub ahead of print) - PubMed
- Giannoukakis N, Trucco M. Gene therapy for type 1 diabetes. Am J Ther. 2005;12:512– 528. - PubMed
Publication types
MeSH terms
Related information
Grants and funding
- R01 EY012689-03/EY/NEI NIH HHS/United States
- P30 EY003040-209005/EY/NEI NIH HHS/United States
- R01 EY012689-02/EY/NEI NIH HHS/United States
- R01 EY012689-02S1/EY/NEI NIH HHS/United States
- P30 EY003040-25S1/EY/NEI NIH HHS/United States
- R01 EY012689-04A2/EY/NEI NIH HHS/United States
- R01 EY012689-06/EY/NEI NIH HHS/United States
- R01 EY012689-01A1/EY/NEI NIH HHS/United States
- P30 EY003040-25/EY/NEI NIH HHS/United States
- R01 EY012689-05/EY/NEI NIH HHS/United States
- P30 EY003040-189005/EY/NEI NIH HHS/United States
- P30 EY003040-199005/EY/NEI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical